Legal & General Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $56.2M | Buy |
|
|||||
|
2025
Q2 | $50.2M | Buy |
|
|||||
|
2025
Q1 | $42.4M | Buy |
|
|||||
|
2024
Q4 | $47.2M | Sell |
|
|||||
|
2024
Q3 | $45M | Sell |
|
|||||
|
2024
Q2 | $55.4M | Sell |
|
|||||
|
2024
Q1 | $55.5M | Sell |
|
|||||
|
2023
Q4 | $58.2M | Sell |
|
|||||
|
2023
Q3 | $50.4M | Sell |
|
|||||
|
2023
Q2 | $43.2M | Sell |
|
|||||
|
2023
Q1 | $50M | Buy |
|
|||||
|
2022
Q4 | $58.7M | Sell |
|
|||||
|
2022
Q3 | $52.8M | Sell |
|
|||||
|
2022
Q2 | $49.4M | Buy |
|
|||||
|
2022
Q1 | $44.4M | Buy |
|
|||||
|
2021
Q4 | $38.1M | Sell |
|
|||||
|
2021
Q3 | $43.2M | Buy |
|
|||||
|
2021
Q2 | $43.6M | Buy |
|
|||||
|
2021
Q1 | $39.4M | Buy |
|
|||||
|
2020
Q4 | $32.5M | Sell |
|
|||||
|
2020
Q3 | $35.4M | Sell |
|
|||||
|
2020
Q2 | $46.1M | Buy |
|
|||||
|
2020
Q1 | $24.5M | Buy |
|
|||||
|
2019
Q4 | $28.1M | Buy |
|
|||||
|
2019
Q3 | $5.75M | Buy |
|
|||||
|
2019
Q2 | $4.42M | Buy |
|
|||||
|
2019
Q1 | $4.54M | Sell |
|
|||||
|
2018
Q4 | $4.33M | Sell |
|
|||||
|
2018
Q3 | $8.01M | Buy |
|
|||||
|
2018
Q2 | $3.91M | Sell |
|
|||||
|
2018
Q1 | $3.72M | Sell |
|
|||||
|
2017
Q4 | $3.52M | Buy |
|
|||||
|
2017
Q3 | $2.24M | Buy |
|
|||||
|
2017
Q2 | $1.47M | Buy |
|
|||||
|
2017
Q1 | $1.27M | Buy |
|
|||||
|
2016
Q4 | $362K | Buy |
|
|||||
|
2016
Q3 | $415K | Buy |
|
|||||
|
2016
Q2 | $318K | Sell |
|
|||||
|
2016
Q1 | $759K | Buy |
|
|||||
|
2015
Q4 | $980K | Buy |
|
|||||
|
2015
Q3 | $628K | Buy |
|
|||||
|
2015
Q2 | $750K | Buy |
|
|||||
|
2015
Q1 | $567K | Buy |
|
|||||
|
2014
Q4 | $258K | Hold |
|
|||||
|
2014
Q3 | $178K | Buy |
|